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E-mail address: doina.popov@icbp.roHyperglycemia, the hallmark of Diabetes mellitus, is a major risk factor for endothelial dysfunction and
vascular complication. In recent years, signiﬁcant achievements have been made in understanding endo-
thelial cell dysfunction triggered by high glucose concentration. The purpose of this review is to discuss
the results of these recent developments. First, the remarkable plasticity of vascular endothelial cell in
response to the high glucose insult is emphasized. This is evident through the switch in the cell’s normal
quiescent proﬁle into new phenotypes, endowed with biosynthetic, inﬂammatory, adhesive, proliferative,
migratory, pro-atherogenic, and pro-coagulant properties, frequently overlapping each other. Then, we
underline the imbalanced expression and activity of transcription and signaling pathways, and the
intense metabolic activity that accompanies the change in endothelial cell phenotype. As an adaptation
to the high glucose-induced biochemical modiﬁcation, a severe alteration of cell structure is produced.
The review concludes with the clinical outcomes of the subject, emphasizing the high glucose-associated
endothelial cell dysfunctional molecules of potential for targeting, and for reducing the impact of hyper-
glycemia on vascular endothelium. Such interventions may lead to a more efﬁcient therapy for the ben-
eﬁt of those diabetic patients who are at increased cardiovascular risk.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Endothelial cells (ECs) are ﬂat epithelial cells that form a mono-
layer that lines the internal lumen of the blood vessels. In normal,
physiological condition, ECs are exposed to circulating blood glu-
cose levels in the range of 3.6–5.8 mmol/L, which are tightly reg-
ulated as part of metabolic homeostasis. The cells are metabolically
active, and produce mediators that affect vascular tone, cell adhe-
sion, and the homeostasis of clotting, and ﬁbrinolysis. Through its
contribution to hemostasis, ECs ensure ﬂuidity of the blood. In nor-
mal conditions, the phenotype of EC is characterized as quiescent,
with turnover rates of the order of months to years. Latest reports
have identiﬁed several molecules that control EC quiescence. These
are the circulating form of human Bone Morphogenetic Protein-9
(BMP-9) [1], the cytosolic phospholipase A2-a when sequestrated
within Golgi apparatus [2], the transcription factor E2-2 (member
of the basic helix–loop-helix family) [3], the very low-density lipo-
protein receptor [4], and Angiopoietin 1 (Ang1), the ligand for the
receptor tyrosine kinase Tie2 [5–7]. Shear stress is also a potent
physiological regulator of EC quiescence. As a biomarker ofellitus. Published by Elsevier Ltd.
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Ovascular quiescence stands the anti-angiogenic R-ras gene expres-
sion [8].2. High glucose concentration induces phenotypic switch and
modiﬁes the intracellular signaling in vascular endothelial cells
Exposure of vascular ECs to glucose levels over than 10 mmol/L
(in vitro or in vivo, as in Diabetes mellitus) is regarded as a high
glucose (HG) condition. The over normal glucose concentration
perturbs cells homeostasis and biochemistry, triggering modiﬁca-
tions both in large vessels (macrovasculature) and in small blood
vessels, such as arterioles, venules, and capillaries (microvascula-
ture). As a consequence of HG concentration, EC quiescence is lost,
cells acquire new phenotypes, their normal function is impaired,
and ‘‘endothelial cell dysfunction” is installed. EC dysfunction is
characterized by one or more of the following features: deﬁciency
in bioavailable nitric oxide (NO), reduced endothelium-mediated
vasorelaxation, hemodynamic deregulation, impaired ﬁbrinolytic
ability, enhanced turnover, overproduction of growth factors, in-
creased expression of adhesion molecules and inﬂammatory genes,
excessive generation of reactive oxygen species (ROS), increased
oxidant stress, and enhanced permeability of the cell layer
[9–12]. In examination of HG effects on vascular EC, one should
also take into account that over physiological glucose concentra-
tions lead to the accelerated formation of multiple biochemicalpen access under CC BY-NC-ND license.
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nonenzymatic reactive Amadori products, 3-deoxyglucosone, diac-
ylglycerol, methylglyoxal, advanced glycation end products (AGEs),
ROS, and nitrosylated species, which further amplify the imbalance
that portrays HG-associated EC dysfunction. ROS production also
triggers the peroxidation of plasma membrane polyunsaturated
fatty acids like linoleic acid and arachidonic acid, generating endog-
enous 4-hydroxy nonenal, a highly reactive carbonyl compound.
The increased oxidative stress seems to be a common alteration,
triggered by a Type 2 diabetesmilieu, inwhich hyperglycemia is ad-
joined by insulin resistance, hyperinsulinemia, and dyslipidemia
[13]. There is a common agreement that endothelial dysfunction
precedes the development of micro- and macrovascular complica-
tions associated with Type 2 diabetes, such as nephropathy,
retinopathy, atherosclerosis, and coronary artery disease; the
underlying mechanism includes the accelerated formation of AGEs,
activation of protein kinase C, increased pro-inﬂammatory signal-
ing, and impaired sensitivity of the PI 3-kinase signaling pathways
[14]. Recent data show that etiopathogenesis of EC dysfunction
differs in Types 1 and 2 diabetes [15]; it is present at the earliest
stages of metabolic syndrome and insulin resistance, and may
precede the clinical diagnosis of Type 2 diabetes by several years
[16].
A ﬁrst issue examined in this overview is the remarkable plas-
ticity of EC in HG conditions, allowing the transition of the normal
quiescent proﬁle into a spectrum of new biosynthetic, pro-inﬂam-
matory, pro-adhesive, migratory, pro-atherogenic, pro-coagulant,
proliferative, pro-apoptotic, and/or senescent phenotypes; these
frequently overlap, e.g. the biosynthetic phenotype is also adhe-
sive, pro-inﬂammatory, and pro-atherogenic, while the pro-
apoptotic phenotype is a senescent one.
As a function of the duration of HG exposure (in vitro) and of
circulating glucose level (in vivo) vascular ECs gradually turn into
biosynthetic cells, endowed with an over developed rough endo-
plasmic reticulum (rER); however, in this condition, the protein
folding process within rER might be affected, and the endoplasmic
reticulum stress is installed [17]. In time, and also as a function of
glucose concentration, ECs enlarged and thickened their basal lam-
ina by mechanisms that involve complex biochemical changes
[18]. To this modiﬁcation contribute TGF-b and its receptor ALK1
[19], ﬁbronectin over expression [20], AGEs [21], as well as AGEs
cross-linking to collagen molecules; the latter products are less
sensitive to degradation, and promote extracellular matrix accu-
mulation [22].
HG concentration also induces pro-inﬂammatory and pro-adhe-
sive phenotypic changes of vascular ECs [23,24]; in these circum-
stances, cell surfaces express adhesion molecules (intracellular
adhesion molecule-1, vascular cell adhesion molecule-1, and endo-
thelial selectin), interleukin (IL)-1b expression becomes up-regu-
lated [24], and secretion of VEGF, IL-8, IL-6, and TNF-a attains
signiﬁcantly increased levels [25]. Along with the typical cytokines
(TNF-a and IL-1b), and chemokines (such as the monocyte chemo-
attractant protein-1), the latest reports emphasize that the pro-
inﬂammatory phenotype of EC is associated with an increased
expression of inﬂammatory genes (e.g. the Neuronatin gene) [26],
with the presence of ROS and phosphorylation of ERK1/2, c-Jun
NH2 – terminal kinase (JNK), NF-kB [23,27,28], and of NF-jB tran-
scription factor inhibitor IkBa [29]. Interestingly, the effect of HG
on this phenotypic change is dependent on the anatomic position
of the vessel, as well as on the duration of diabetes. Thus, regions
of arteries exposed to low shear stress are susceptible to inﬂamma-
tion, whereas regions exposed to high shear stress are protected; in
the latter areas, the transcription factor NF-E2-related factor 2
inhibits p38 phosphorylation, and suppresses EC dysfunction [30].
Moreover, the duration of diabetes selectively up-regulates the
inﬂammatory genes expression, i.e. in short-term diabetes, themRNA transcripts for chemokine ligands CCL2 and CCL5 were up-
regulated in the aortic ECs, while at later stages of diabetes these
genes were up-regulated in both the aortic and venous ECs [31].
HG signiﬁcantly enhanced the migration of ECs (within the ret-
ina) concomitant with the sustained activation of the downstream
prosurvival and promigratory signaling pathways, including Src
kinase, phosphatidylinositol 3-kinase/Akt1/endothelial NO syn-
thase, and ERKs [32]. Recent reports demonstrate that EC migration
is NO-induced in a process, which implies the inactivation of the
transcription factor FOXO3a and subsequent down-regulation
of peroxisome proliferator-activated receptor ccoactivator 1a
(PGC-1a) [33]. Much of the current literature deals with the migra-
tory properties of ECs as manifest in the angiogenesis process, and
with endothelial progenitor cells (EPCs) migration during vascular
repairs. Although these issues are beyond the subject of this re-
view, an interesting recent report underlines that Type 2 Diabetes
mellitus impairs EPC migration, in a process linked to the stimula-
tion of CXC receptor-4 (CXCR4) and activation of PI3K/Akt/eNOS
signaling pathway [34].
Interestingly, although hyperglycemia is acknowledged to be an
independent risk factor for developing diabetes-associated athero-
sclerosis, the pro-inﬂammatory environment in diabetes is the crit-
ical factor conditioning the early pro-atherosclerotic actions of HG
[35]. Reportedly, the presence of hyperglycemia stimulates expres-
sion of thioredoxin-interacting protein (TXNIP) [36] with a possible
role in the EC pro-atherosclerotic response to extracellular
diabetic-like environment [37].
Another imbalance associated with the effect of HG concentra-
tion is the promotion of a pro-coagulant condition of endothelium
(by production of pro-coagulant mediators such as plasminogen
activator inhibitor-1, ﬁbrinogen, and P-selectin) associated with a
reduced ﬁbrinolitic activity [15,38]. Reportedly, Type 2 diabetes
patients may be especially vulnerable to prothrombotic events
when hyperglycemia is concurrent with systemic inﬂammation
[39]. Not only is the endothelial cell affected by HG, but also the
circulating cells. Thus, a recent report emphasizes that a glucose-
regulated protein (GRP78) is involved in platelet deposition during
interaction with the vascular wall [40].
High glucose concentration may also trigger two opposed phe-
notypic changes of vascular EC: in some circumstances, EC turns
into proliferative, while in others, into apoptotic. An important
player in the induction of EC proliferation is nicotinamide phos-
phoribosyltransferase (Nampt); which enables cells to resist HG
concentration, and to use excess glucose to support replicative lon-
gevity and angiogenic activity [41]. For the retinal ECs exposed to
HG, it was demonstrated that proliferation was accelerated as
the number of pericytes gradually decreased [42]. The altered
hemodynamic forces generated by changes in blood ﬂow, inﬂuence
also EC proliferation [43]. Although there is a common agreement
on HG concentration as an inductor for EC apoptosis [44,45], the
circumstances that favor this process are diabetes duration (via
selective up-regulated caspase-1mRNA) [31], the sequential acti-
vation of ROS, JNK, and caspase-3 [46,47], the down-regulation of
connexins Cx43 [48], Cx37, and Cx40 [49], and the presence of
auto-antibodies in patients with macular edema or progression
to albuminuria [50]. The intracellular consequences of EC apoptotic
changes consist in DNA fragmentation, and mitochondrial dysfunc-
tion, manifest by alteration of membrane potential, release of cyto-
chrome-c, and mitochondrial fragmentation, and these changes
play a potential pathogenic role in mediating the risk of Type 2
Diabetes mellitus. Thus, defective or insufﬁcient mitochondrial
function may lead to the chronic accumulation of lipid oxidative
metabolites that can mediate insulin resistance and secretory dys-
function [48,51,52].
Moreover, in HG condition, a senescent phenotype of EC occurs
[53]; reportedly, cell turnover and oxidative stress are engaged in
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Other contributors to the senescent phenotype of EC are the de-
creased expression of NAD+-dependent deacetylase sirtuin1, and
the activation of p53 acetylation [55].
Taken together, the multitude of new phenotypes acquired by
EC under the insult of HG concentration reveals remarkable cell
plasticity, linked to the alteration of speciﬁc molecules and intra-
cellular pathways. Comprehensive recent reports advanced deeper
into EC biochemistry in HG conditions, unveiling the mechanisms
that underlie its intense metabolic activity.3. High glucose concentration intensiﬁes the metabolic activity
of vascular endothelial cells
The intensiﬁcation of metabolic activity of ECs exposed to HG is
the result of an imbalance between up-regulation of several tran-
scription and signaling factors, and down-regulation of other intra-
cellular molecules. Examples of activated transcription factors are
the aryl hydrocarbon receptor transcription factor [56], p300 (a
transcriptional co-activator with histone acetyl transferase activ-
ity) [57], and COUP-TFII (the chicken ovalbumin upstream
promoter-transcription factor II) [58]. In human umbilical vein
ECs, HG has time-dependent effects on COUP-TFII, i.e. the short-
term (60–240 min) HG stimulation increases its expression, while
long term stimulation (48 h) down-regulates its expression [58].
Other laboratories reported that HG treatment and diabetes pro-
duced a deregulated activation of ETS (E-twenty six), one of the
largest families of transcription factors; this activation blocks the
functional activity of progenitor cells and their commitment to-
ward the EC lineage [59]. Another activated transcription factor
is FOXO1; the mechanism is triggered by HG, acting through oxida-
tive stress pathway. Subsequently, activated FOXO1 promotes
inducible nitric oxide synthase (iNOS)-dependent NO-peroxyni-
trite generation, which leads in turn to LDL oxidation and eNOS
dysfunction [60]. Moreover, in diabetic rats, the activation of tran-
scription factor FOXO1 was linked to retinal microvascular cell loss
[61].
In HG conditions, as well as in diabetes, activation of EC intra-
cellular signaling pathways occurs. The recent data emphasize
the activation of JAK2/STAT3 pathway and of Vascular Endothelial
Growth Factor (VEGF) [62], of NAD(P)H oxidase followed by ROS
generation [63], and of protein kinase C [13]. Among the last family
of enzymes, the activation of PKC-a, -b1/2, and PKC-d isoforms is
linked to the development of diabetes pathologies affecting both
large vessels (in atherosclerosis and cardiomyopathy) and small
vessels (in retinopathy, nephropathy, and neuropathy) [64].
Another modiﬁcation induced by HG is the augmented expres-
sion of lipid peroxidation products [65], methylglyoxal (an AGE
precursor molecule) [66], angiotensin II receptor 1 [67], neutro-
phins p75 receptor [68], Transient Receptor Potential ion channel
protein 1 [69], poly(adenosine diphosphate-ribose) polymerase,
[70], and ﬁbronectin [20]. The intracellular calcium [Ca2+]i concen-
tration is also enhanced by HG condition [71]. A further character-
istic of EC dysfunction triggered by HG consists in the increased
production of vasoconstrictor prostanoids (endoperoxides and
prostacyclin) that activate Thromboxane A2 (TP) receptors on the
underlying SMCs, contributing to ampliﬁed vascular wall contrac-
tility [72].
In contradistinction to the above-mentioned activating effects,
HG concentration down-regulates a variety of EC molecules. Exam-
ples are the AGER1 (an AGE-receptor that counteracts Receptor for
Advanced Glycation End products (RAGE)) [73], UCP2 [63], and
eNOS. As shown by the latest reports, the mechanisms that may ac-
count for the decline in eNOS activity consist in enhanced ROS for-
mation by NADPH oxidase and uncoupled eNOS [74], diminishedHsp-90–eNOS interaction, due to the reaction between heat shock
protein-90 and the inhibitor jB kinase (IKK)b [75], and inhibition
of enzyme activity of dimethylarginine dimethylaminohydrolase,
resulting in an accumulation of asymmetric dimethylarginine;
the latter competes with the eNOS substrate, L-arginine, and inhib-
its NO formation [76]. Such a mechanism explains the other char-
acteristic of EC dysfunction in hyperglycemia and Diabetes
mellitus, i.e. the impeded endothelium-dependent relaxation of
the vascular wall. The mitochondria are also vulnerable in HG-
exposed ECs; dysregulation in fuel-sensing molecules, AMP-activated
protein kinase (AMPK), and the histone/protein deacetylase SIRT1
predisposes to Type 2 diabetes and atherosclerotic cardiovascular
disease [77]. The cellular fueling system (the tricarboxylic acid oxi-
dation cycle and the fatty acid b-oxidation pathway) is a target for
various noxious stimuli, some generated within mitochondria
themselves, such as the ROS [78]. Overproduction of the latter by
mitochondrial electron transport chain serves as a causal link be-
tween elevated glucose and three major pathways responsible
for hyperglycemic damage, i.e. the activation of the hexosamine
pathway, the increased formation of AGE, and the activation of
PKC isoforms [17].
Collectively, the imbalanced biochemical pathways (described
above) portray the dysfunctional condition of EC facing HG concen-
tration either in vitro or in vivo, as in diabetic vasculature. As an
adaptation to the modiﬁed biochemistry and dysfunction, a modi-
ﬁcation to cellular structure is produced. In time, the structural
modiﬁcations aggravate damaging the EC and the vascular wall.4. High glucose concentrationmodiﬁes vascular endothelial cell
ultrastructure
To evaluate HG-induced alterations of EC structure, the basic
features of cells’ normal ultrastructure are brieﬂy mentioned. EC
plasmalemma expose differentiated macro- and micro-domains
and membrane-associated receptors; the cells contain coated vesi-
cles and caveolae (formerly known as plasmalemmal vesicles) en-
dowed with speciﬁc receptors, and transendothelial channels
[79]. The EC is quiescent in physiologic conditions (see Section 1),
display rather rare organelles involved in biosynthetic activities
(rER and Golgi apparatus) or in degradations (such as multivesicu-
lar bodies, a lysosomal like compartment, and lysosomes), and pro-
duce a unique, thin basal lamina. The ultrastructural alterations
induced by HG in vascular ECs are documented both by in vitro (hu-
man aortic ECs cultured for 1–2 weeks in a medium supplemented
with 25 mM D-glucose) and in vivo studies (the vasculature of mice
and golden Syrian hamsters at 6 weeks and 6 months, respectively
after streptozotocin injection) [80,81]. The common morphologic
feature is the gradual and signiﬁcant enrichment of biosynthetic
organelles. As examples, the Golgi complex is evident in the aortic
and capillary ECs (Fig. 1a and b), and the abundance in rER is obvi-
ous in ECs of the athero-susceptible aortic arch (Fig. 1c), of retinal
venules (Fig. 1d), and of the femoral artery (Fig. 1e). Reportedly, dia-
betes imparts diffuse endothelial perturbation in both arterial and
venous endothelium [31]. Morphologic evidence for the cells’ active
metabolism is also provided through the presence of multivesicular
bodies on electron-micrographs. One to three copies of these
organelles are evident per EC in capillaries of retinal inner layer of
diabetic animals (Fig. 1f).
As a result of prolonged and direct contact with the hyperglyce-
mic milieu, mitochondrial fragmentation occurs [51], and the cel-
lular cytoskeleton is reorganized; the latter occupies almost the
entire cytoplasm in myocardial capillary ECs (Fig. 1g); others have
reported recently the reorganization of actin ﬁlaments in human
ECs exposed to nonenzymatically glycated bovine serum albumin
[12]. In addition, the intact microtubule and actin cytoskeleton is
Fig. 1. Electron microscopic images of endothelial cells morphology in various vascular beds of streptozotocin-injected mice and hamsters (at 4 weeks since induction of
diabetes). (a) Aortic endothelium; (b, g, and h) myocardial capillary endothelium; (c) aortic arch endothelium; (d) retinal venular endothelium; (e) femoral artery
endothelium; (f and i) capillary endothelium of the retina inner layer. EC, endothelial cell; l, vascular lumen; mvb, multivesicular body; Go, Golgi apparatus; rER, rough
endoplasmic reticulum; WPb, Weibel Palade body; f, cytoskeletal ﬁlaments; m, mitochondria; bl, basal lamina; c, collagen; ecm, extracellular matrix; CM, cardiomyocyte;
SMC, smooth muscle cell. Bars: a, c, e, and g: 0.12 lm; b and h: 0.27 lm; d: 0.183 lm; f and i: 0.081 lm.
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mia [23].
It is generally recognized that diabetes is associated with the
thickening of the capillary ECs basal lamina; we show here that ba-
sal lamina turns into a folded structure (Fig. 1h), and generates
reduplications with a multilayer appearance (Fig. 1i); this phenom-
enon was also observed at the interstitial capillaries of diabetic
golden Syrian hamsters [82] and at the endoneurial capillaries of
diabetic cats [83]. Functionally, the thickening of EC basal lamina
impairs the amount and selectivity of transport of metabolic prod-
ucts and nutrients between circulation and the tissues [84]. To-
gether, the above ultrastructural modiﬁcations are associated
with the biosynthetic phenotype of vascular ECs.
On electron-micrographs, the proliferative phenotype of endo-
thelium is assessed by the presence of two centriols (paired organ-
elles involved in mitosis) in close proximity to each other (Fig. 2).
Since the ultrastructural changes appear as secondary to the bio-
chemical alterations and EC dysfunction, in order to alleviate them,
it is essential to ﬁnd the optimal moment for therapeutic interven-
tion, when the molecular alterations are still reversible. Examples
for uncovering such issues are illustrated by ongoing research.5. Potential clinical outcomes: toward the attenuation of ECs
disturbances induced by hyperglycemia
Themain goal of translationalmedicine is to target the disturbed
molecules/pathways in therapies aimed at attenuating HG-triggered EC dysfunction. The majority of such strategies intend
to reduce the oxidative stress generated in hyperglycemia/diabetes
by using a plethora of antioxidantmolecules. Mitochondria-derived
ROS generation can be inhibited by Pigment Epithelium-Derived
Factor (PEDF) that also decreases lipid peroxidation, and down-
regulates VEGF; thus it appears that PEDF treatment may be bene-
ﬁcial in diabetic retinopathy [62,65]. Moreover, azaserine functions
as antioxidant and protects against hyperglycemic endothelial
damage [23]. ROS generation in EC can be regulated by over-
expression of certain molecules, such as transcription factor NF-
E2-Related Factor-2, AGER1, peroxisome proliferator-activated
receptor-cco-activator 1-a, and AMP-activated protein kinase
(AMPK) [73,85–87]. Activation of the latter suppresses 26S protea-
some-mediated degradation of GTP-cyclohydrolase and up-regu-
lates mitochondrial UCP2, resulting in the inhibition of superoxide
anion production and prostacyclin synthase nitration; the ﬁnal re-
sult is the prevention of the oxidative stress induced by hyperglyce-
mia and the normalization of EC function [63,88]. In line with this,
the mammalian homolog of the ﬁsh calcium regulatory hormone
stanniocalcin-1 attenuates endothelial superoxide anions genera-
tion and activation of inﬂammatory pathways, and maintains
tight junctionproteins expression, preserving the ECmonolayer seal
[28].
As for the attenuation of inﬂammatory pathways activation, a
potential therapeutic method that improves vascular barrier func-
tion consists in targeting key signaling molecules that mediate
endothelial-junction-cytoskeleton dissociation [89]. A further
approach is to inhibit the activity of certain molecules in speciﬁc
Fig. 2. Proliferative endothelial cells in a myocardial capillary (a) and a brain capillary (b) of streptozotocin-injected hamster (at 4 weeks since induction of diabetes). EC,
endothelial cell; l, vascular lumen; Go, Golgi apparatus; c, centriol; ecm, extracellular matrix; CM, cardiomyocyte. Bars: a: 0.12 lm; b: 0.183 lm.
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gen synthase kinase 3b reduced adhesion molecules expression,
and decreased endothelial leukocyte adhesion under inﬂammatory
conditions [90]; in diabetic retinopathy, inhibition of a4 integrin/
CD49d signaling pathway attenuated the diabetes-induced up-
regulation of NF-kB activation, reduced leukocyte adhesion to EC
surface, and thus may hold promise for the clinical activity [91].
Another useful molecule is sphingosine-1-phosphate that inducts
the expression of MAP kinase phosphatase-3, inhibiting the high-
glucose-mediated ERK1/2 phosphorylation and exerting an anti-
inﬂammatory effect on diabetic ECs [92].
The accelerated proliferation of retinal ECs and the decrease in
pericytes number can be prevented through the addition of bioac-
tive TGF-b and by aldose reductase inhibition [42]. In addition,
enhancing endothelial Nampt activity may be beneﬁcial in scenar-
ios requiring ECs-based vascular repair and regeneration during
HG, such as diabetes-related vascular disease [41].
Inhibition of ECs migration can be achieved by activating Acti-
vin Receptor-Like Kinase 1 [93]. Moreover, enhanced production
of thrombospondin (TSP2) is described as an inhibitor of EC migra-
tion and capillary morphogenesis during neovascularization [94].
The latest reports also indicate possible strategies for reducing
ECs apoptosis and senescence. Reportedly, the HG-induced apopto-
sis is reduced by fenoﬁbrate [44] and is inhibited by quercetin sul-
fate/glucuronide, the metabolite of quercetin in blood [47].
Moreover, enhanced IGF-1 signaling inhibits glucose-induced
apoptosis in human umbilical vein ECs by reducing mitochondrial
dysfunction, and maintaining the mitochondrial retention of cyto-
chrome-c [95]. The prevention of HG-induced EC senescence is ex-
erted by the activation of Sirt1 (a NAD-dependent deacetylase) or
disruption of p53 pathway [55]. L-arginine also exerts an anti-
senescence effect on human umbilical vein ECs exposed to
33 mmol/L glucose (via the PI3K/Akt pathway), and the authors
claim it might be a therapeutic agent for diabetic vascular compli-
cations [53]. In addition, statins and peroxynitrite scavengers pos-
sess the ability to reduce senescence in laboratory models of
disease (reviewed in Ref. [54]).
In summary, three systems may at present alleviate HG-
induced vascular EC dysfunctional proﬁles: exposure to inhibitors
of certain molecules/pathways or down-regulation of speciﬁc mol-
ecules, activation or over-expression of particular molecules and
intracellular pathways, and correction of biochemical alterations
(if still reversible) towards rehabilitation of the quiescent condi-
tion. Although translational medicine may potentially target the
intracellular molecules/pathways identiﬁed thus far (as shown
above), the avenue is far from reaching an end. Still not well under-
stood are the time-dependence and the vascular bed speciﬁcity of
HG-induced EC biochemical changes, and substantiation of mech-
anisms which operate in continuous, fenestrated or discontinuousendothelia. Less clear still are the intracellular pathways which
lead to basal lamina reduplication in HG conditions. In addition,
despite the recent progress made in reducing the HG-associated
deleterious effects on EC, the existence of a causal relationship be-
tween telomere dysfunction and endothelial senescence is yet to
be demonstrated [54].6. Concluding remarks
This literature reviewed outlines the most recent mechanisms
underlining EC dysfunction, triggered by over-physiological glucose
concentration. Modiﬁed biochemistry is linked to the phenotypic
switch of EC that acquires new properties (biosynthetic, inﬂamma-
tory, adhesive, migratory, pro-atherogenic, pro-coagulant, prolifer-
ative, apoptotic or even senescent), rather than overlapping
each other. Such changes are associated with the diabetic vasculop-
athy of large vessels and microvasculature. The results of the
ongoing studies emphasize substantial progress in identifying EC-
disturbed molecules/pathways under the insult of HG; and these
may hold therapeutic potential, and be of beneﬁt to the diabetic
patient.
Finally, it is important to point out that the reported effects of
HG concentration are not the outcome of a unique insult, but of
a multitude of deleterious molecules formed in HG conditions.
These include the nonenzymatic glycation products, the AGE-pro-
teins, the oxidant free radical species, among other components
of the diabetic environment. Moreover, under insulin resistant con-
ditions, as in Type 2 Diabetes mellitus, increased insulin concentra-
tions and/or impaired insulin-signaling pathways may also
contribute to endothelial dysfunction [13]. Therefore, the effects
of HG emphasized in the largest part of the literature reviewed
here should be viewed within the more complex perspective of
the diabetic milieu.
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